The Stimulant Treatment Gap: NIDA 2026 Update on a Crisis With No Approved Cure
Cocaine and methamphetamine together drive tens of thousands of deaths annually. The NIDA Clinical Trials Network 2026 update shows how far the field still has to go.
The Stimulant Treatment Gap: NIDA’s 2026 Update on a Crisis With No Approved Cure
The NIDA Clinical Trials Network’s Stimulant Use Disorder (StUD) Task Force published its 2026 update in April, and the core finding remains what it has been for years: there are no FDA-approved medications for cocaine use disorder or methamphetamine use disorder.
That gap is not a minor footnote. Stimulant deaths — primarily methamphetamine and cocaine — reached 57,500 in 2022, with roughly 70% of those deaths involving fentanyl in the drug supply (polysubstance overdose). Stimulant-involved deaths have continued rising even as opioid-only deaths declined. People who use stimulants and opioids simultaneously face dramatically elevated overdose risk.
The treatment landscape today relies heavily on contingency management — providing structured incentives for treatment participation and negative drug tests — which NIDA identifies as the most evidence-based behavioral treatment for both methamphetamine and cocaine use disorder. But contingency management is unavailable in most treatment settings due to regulatory barriers, stigma, and reimbursement challenges.
NIDA’s research pipeline includes several promising directions: monoclonal antibodies designed to bind cocaine or methamphetamine in the bloodstream before the drug crosses the blood-brain barrier, sequestrant molecules that similarly encapsulate methamphetamine, and repurposed existing medications (bupropion, naltrexone combinations) showing signal in subpopulations.
An exenatide (a GLP-1 agonist) trial for cocaine use disorder is also ongoing, following the broader signal from semaglutide’s alcohol data — suggesting that GLP-1 receptor modulation may reach stimulant disorders too.
Why This Matters for People in Recovery
Tens of millions of people have experience with stimulant use, and the lack of an approved medication is a real barrier to recovery pathways that work for opioid use disorder. Rize Recovery’s matching tool includes facilities with contingency management programs. Find evidence-based treatment near you.
Sources Cited
- 01.ANIDA CTN Stimulant Use Disorder Task Force 2026 UpdatePubMed / NIDA CTN
- 02.ACocaine - NIDANIDA
Filed Under
sciencetreatmenttrendsCocaineMethamphetamineContingency Management
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Minnesota's Opioid Deaths Fell Again. The Stimulant Deaths Don't Have an Antidote Waiting.
Minnesota's 2025 data shows opioid deaths falling for a third year while stimulant overdoses climb. Naloxone does nothing for meth or cocaine. Here is what does.
The Crisis, By the NumbersHHS Says Opioid Deaths Are at a Decade Low. The Number It Led With Isn't an Opioid Number.
HHS says opioid deaths are at their lowest in nearly a decade, but the headline figure is an all-cause death rate. Minnesota's new data shows where the deaths are moving.
The Crisis, By the NumbersThe Overdose Decline Has a Hole in It, and Meth Is Standing in It
Minnesota's 2025 overdose deaths rose 3% while opioid deaths held flat and stimulant deaths climbed. Kentucky's meth deaths fell and meth still became the most common drug found. What providers and people who use can do this week.